How to Buy Exelixis Stock
Exelixis Inc
Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
Exelixis stock last closed at $22.52, up 0.13% from the previous day, and has increased 17.54% in one year. It has overperformed other stocks in the Biotechnology industry by 0.43 percentage points. Exelixis stock is currently +24.56% from its 52-week low of $18.08, and -7.48% from its 52-week high of $24.34.
As of Apr 19, 2024, there are 303.19M shares of EXEL outstanding. The market cap of EXEL is $6.83B. In the past 24 hours, 2.33M EXEL shares were traded.
How to Buy Exelixis Stock
Wondering how to invest in Exelixis stock? Here's how.
- Choose where to buy Exelixis stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Exelixis stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Choose your method of payment and add your information.
- Analyze Exelixis stock: The Exelixis ticker symbol is EXEL. Is Exelixis stock a good investment? Should you buy shares of EXEL? How do EXEL's underlying business fundamentals look? Do top analysts think Exelixis is a good buy? Why has EXEL's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if EXEL is a good stock to buy).
- Execute your EXEL trade: Decide if you will purchase EXEL shares at the current market price or use a limit order to purchase EXEL stock at a particular price.
- Watch your EXEL position: Create a watchlist to track your investment in Exelixis shares.
Step 1: Choose where to buy Exelixis stock
You will need a brokerage account in order to access the NASDAQ market and buy EXEL stock.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Financial Services, New York to Tokyo — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro today.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal details so you can invest in EXEL stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to create a new trading account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've finished signing up on investing apps, you need to deposit funds:
Watch this video walkthrough to see the process of depositing funds into your investment account.
Step 4: Analyze Exelixis stock
After you have identified the best place to buy Exelixis stock, it's crucial to research their stock before you invest, so you can comprehend the risk and upside.
Exelixis Metrics
Exelixis Due Diligence Checks
WallStreetZen was created to help average investors perform better fundamental analysis quickly.
You can view all of the due diligence checks on EXEL's stock page.
Is EXEL stock overvalued?
You can use many financial metrics, analyses, models, and charts to gauge EXEL's fair value.
Using relative valuations methods:
- EXEL could be overvalued based on its P/E ratio of 34.65x, relative to Biotechnology industry P/E ratio of 15.81x
- EXEL may be undervalued based on its P/B ratio of 3.02x, relative to Biotechnology industry P/B ratio of 5.74x
- EXEL may be undervalued based on its PEG ratio of 0.62x
You can access additional valuation analysis on EXEL's stock here.
A look at EXEL Cashflows and Balance Sheet
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the EXEL balance sheet.
- There are more short-term assets than long-term liabilities on the EXEL balance sheet.
- EXEL's operating cash flow of $333.32M allows it to safely service it's debt of $189.94M.
- EXEL earnings of $257.52M is not enough to cover its interest payments.
- EXEL profit margin has gone up from 11.3% to 11.4% in the past year.
- EXEL has a low debt to equity ratio of 0.3.
Negative Health Checks:
- Total EXEL debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy Exelixis stock
Out of 6 Wall Street analysts who give forecasts on EXEL, the consensus analyst rating on EXEL is a Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest EXEL Analyst Recommendations
David Lebovitz, a bottom 11% analyst from Citigroup initiates coverage on EXEL with a strong buy rating and announces their EXEL price target of $31.00, on Dec 15, 2023.
Jefferson Harralson, an analyst from Morgan Stanley maintains EXEL with a hold rating and raises their EXEL price target from $22.00 to $23.00, on Nov 2, 2023.
You can dive deeper into what analysts are projecting on the Exelixis stock forecast page.
EXEL Trading Indicators
Is EXEL Growing Revenue?
Last year, EXEL earnings were $207.77M. Over the last five year, EXEL's earnings have increased by -22.47% per year. This was slower than the Biotechnology industry average of 15.96%.
Last year, EXEL revenue was $1.83B. Over the last five year, EXEL's revenue has gone up by 16.47% per year. This was slower than the Biotechnology industry average of 28.92%.
Find out more about EXEL's earnings and revenue performance here.
What are EXEL executives and large shareholders up to?
In the last 12 months, executives and large shareholders at EXEL have sold more shares than they have bought.
Alan M. Garber, Director of EXEL, was the latest EXEL insider to sell. They sold $461,112.05 worth of EXEL shares on Mar 21, 2024.
Research more about who owns EXEL shares here.
Can I get consistent income from EXEL stock?
No, Exelixis doesn't provide an income stream by paying out dividends.
What others are saying about EXEL
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your EXEL trade
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly the best for newer investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a particular price limit, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you need more help with buying stocks on eToro, watch the helpful video below:
Step 6: Watch your EXEL position
Now that you own some shares in EXEL, you'll want to stay up-to-date on your shares.
Make a watchlist to keep track of your EXEL stock.
EXEL Feed
How to Buy Stock in Exelixis
To reiterate, here are the 6 steps to buy stock in Exelixis:
- Choose where to buy Exelixis stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Analyze Exelixis stock
- Execute your EXEL trade
- Watch your EXEL position
If you require a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you would like to track your new investment in Exelixis, create a watchlist on WallStreetZen today.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.